Payment overview · 2025
General Payments
$36.65
2 reported records · 1 companies
Healthcare provider profile · identity verified
Nancy Gregory, A.R.N.P.
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · PULLMAN, WA · NPI 1801954003
Verified facts
What the public records show
CMS Open Payments records show Nancy Gregory, A.R.N.P. received $36.65 in general payments during 2025 across 2 reported records.
Celgene Corporation accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Celgene Corporation | Unresolved — no canonical attribution shown | $36.65 | 100.0% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $36.65 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $36.65 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
136 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 353 | 82 |
| Lisinopril | Lisinopril | 276 | 63 |
| Levothyroxine Sodium | Levothyroxine Sodium | 264 | 55 |
| Gabapentin | Gabapentin | 214 | 36 |
| Losartan Potassium | Losartan Potassium | 180 | 44 |
| Metformin Hcl Er | Metformin Hcl | 172 | 39 |
| Amlodipine Besylate | Amlodipine Besylate | 171 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 170 | 35 |
| Metformin Hcl | Metformin Hcl | 153 | 40 |
| Furosemide | Furosemide | 142 | 30 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 142 | 21 |
| Jardiance | Empagliflozin | 138 | 26 |
| Eliquis | Apixaban | 136 | 25 |
| Potassium Chloride | Potassium Chloride | 136 | 28 |
| Omeprazole | Omeprazole | 133 | 35 |
| Simvastatin | Simvastatin | 122 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 118 | 20 |
| Allopurinol | Allopurinol | 105 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 104 | 29 |
| Tramadol Hcl | Tramadol Hcl | 102 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 99 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 86 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 82 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 79 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 77 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 74 | 18 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 67 | 19 |
| Lovastatin | Lovastatin | 67 | 17 |
| Alendronate Sodium | Alendronate Sodium | 66 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 65 | 12 |
| Montelukast Sodium | Montelukast Sodium | 64 | 13 |
| Bupropion Xl | Bupropion Hcl | 63 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 62 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 57 | 13 |
| Spironolactone | Spironolactone | 56 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 53 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 53 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 52 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 50 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 49 | 15 |
| Humalog Kwikpen U-100 | Insulin Lispro | 48 | 13 |
| Ozempic | Semaglutide | 47 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 43 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 42 | suppressed |
| Cephalexin | Cephalexin | 38 | 20 |
| Farxiga | Dapagliflozin Propanediol | 38 | suppressed |
| Novolog Flexpen | Insulin Aspart | 38 | 14 |
| Trulicity | Dulaglutide | 38 | suppressed |
| Myrbetriq | Mirabegron | 36 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | suppressed |
| Glipizide | Glipizide | 34 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 34 | suppressed |
| Acyclovir | Acyclovir | 33 | suppressed |
| Ezetimibe | Ezetimibe | 33 | suppressed |
| Pregabalin | Pregabalin | 33 | suppressed |
| Finasteride | Finasteride | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | suppressed |
| Memantine Hcl | Memantine Hcl | 31 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 31 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 31 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Mounjaro | Tirzepatide | 30 | suppressed |
| Glimepiride | Glimepiride | 29 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 27 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | suppressed |
| Prednisone | Prednisone | 26 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Insulin Lispro | Insulin Lispro | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Verapamil Er | Verapamil Hcl | 25 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 24 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 23 | suppressed |
| Rybelsus | Semaglutide | 23 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 22 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 22 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Admelog Solostar | Insulin Lispro | 16 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Famotidine | Famotidine | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Azithromycin | Azithromycin | 14 | 12 |
| Carvedilol | Carvedilol | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Serevent Diskus | Salmeterol Xinafoate | 12 | suppressed |
| Zaleplon | Zaleplon | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Ursodiol | Ursodiol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $36.65 · 2 records | Celgene Corporation | ZEPOSIA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Celgene Corporation?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error